Analysis of human lung mast cells by single cell RNA sequencing

Front Immunol. 2023 Mar 30:14:1151754. doi: 10.3389/fimmu.2023.1151754. eCollection 2023.

Abstract

Mast cells are tissue-resident cells playing major roles in homeostasis and disease conditions. Lung mast cells are particularly important in airway inflammatory diseases such as asthma. Human mast cells are classically divided into the subsets MCT and MCTC, where MCT express the mast cell protease tryptase and MCTC in addition express chymase, carboxypeptidase A3 (CPA3) and cathepsin G. Apart from the disctintion of the MCT and MCTC subsets, little is known about the heterogeniety of human lung mast cells and a deep analysis of their heterogeniety has previously not been performed. We therefore performed single cell RNA sequencing on sorted human lung mast cells using SmartSeq2. The mast cells showed high expression of classical mast cell markers. The expression of several individual genes varied considerably among the cells, however, no subpopulations were detected by unbiased clustering. Variable genes included the protease-encoding transcripts CMA1 (chymase) and CTSG (cathepsin G). Human lung mast cells are predominantly of the MCT subset and consistent with this, the expression of CMA1 was only detectable in a small proportion of the cells, and correlated moderately to CTSG. However, in contrast to established data for the protein, CPA3 mRNA was high in all cells and the correlation of CPA3 to CMA1 was weak.

Keywords: carboxypeptidase A3 (CPA3); cathepsin G (CTSG); chymase (CMA1); heterogeniety; lung; mast cells (MC); single cell RNA sequencing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cathepsin G
  • Chymases / genetics
  • Chymases / metabolism
  • Humans
  • Lung / metabolism
  • Mast Cells* / metabolism
  • Peptide Hydrolases* / metabolism
  • Sequence Analysis, RNA
  • Tryptases / genetics
  • Tryptases / metabolism

Substances

  • Chymases
  • Cathepsin G
  • Peptide Hydrolases
  • Tryptases

Grants and funding

This study was supported by grants from the Swedish Research Council (2018-02070, 2020-01693, and 2022-00558); the Heart-Lung Foundation; The Swedish Cancer Society; the Ollie and Elof Ericssons Foundation, the Ellen, Walter and Lennart Hesselman Foundation; the Tore Nilsson Foundation; the Lars Hierta Memorial Foundation; the Konsul Th C Bergh Foundation; the Tornspiran Foundation; the O. E. and Edla Johanssons Foundation; the Swedish Society for Medical Research; The Magnus Bergvall Foundation; The Åke Wiberg Foundation; The Centre for Allergy Research Highlights Asthma Markers of Phenotype (ChAMP) consortium funded by the Swedish Foundation for Strategic Research; the AstraZeneca & Science for Life Laboratory Joint Research Collaboration; the Vårdal Foundation and the Karolinska Institutet. The authors declare that this study received funding from AstraZeneca. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.